|Year : 2019 | Volume
| Issue : 4 | Page : 481-485
Topical ciclopirox olamine 1%: Revisiting a unique antifungal
Sidharth Sonthalia1, Mahima Agrawal2, VN Sehgal3
1 Department of Dermatology and Dermatosurgery, Skinnocence, The Skin Clinic and Research Centre, Gurugram, Haryana, India
2 Department of Dermatology and STD, LHMC and Associated Hospitals, Panchwati-Delhi, India
3 Dermato Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati-Delhi, India
|Date of Web Publication||28-Jun-2019|
Department of Dermatology and Dermatosurgery, Skinnocence: The Skin Clinic and Research Centre, Gurugram - 122 009, Haryana
Source of Support: None, Conflict of Interest: None
| Abstract|| |
The injudicious use of antifungals, indiscriminate use of corticosteroids for instant relief, persistence of predisposing factors like sweat retention and uncontrolled diabetes, and emerging resistance to antifungals across the globe have rendered the management of an erstwhile simple infection, the superficial cutaneous mycoses highly complicated and tricky. Ciclopirox is an old yet efficacious, versatile, and safe topical antifungal of the hydroxypyridone family. Despite its numerous beneficial properties over the majority of other topical antifungals, it remains underutilized.
Keywords: Candida, ciclopirox olamine, dermatophyte, mycoses, pityriasis versicolor, seborrheic dermatitis, tinea
|How to cite this article:|
Sonthalia S, Agrawal M, Sehgal V N. Topical ciclopirox olamine 1%: Revisiting a unique antifungal. Indian Dermatol Online J 2019;10:481-5
|How to cite this URL:|
Sonthalia S, Agrawal M, Sehgal V N. Topical ciclopirox olamine 1%: Revisiting a unique antifungal. Indian Dermatol Online J [serial online] 2019 [cited 2020 Jun 2];10:481-5. Available from: http://www.idoj.in/text.asp?2019/10/4/481/261783
Ciclopirox olamine (CPO) is a hydroxypyridone derivative that differs in structure and mechanism of action from the other known antifungal agents. This topical antifungal agent has been in use for over three decades and received its US-FDA approval in June 2004. The majority of extant literature revolves around its nail lacquer formulation used for the treatment of onychomycosis; however, its topical cream formulation remain grossly underutilized. The main focus of this article will be on the cream formulation. The pleiotropic effects and certain unique properties of CPO make a strong case for its resurgence as a topical antifungal.
The molecule exists in its free acid form known as ciclopirox and in its salt form as CPO. CPO 1% is equivalent to 0.77% ciclopirox. Ciclopirox remains the active compound, with no additional antifungal contribution by the olamine group. It is a broad-spectrum antifungal medication with additional antibacterial and anti-inflammatory properties (vide infra).
Hydroxypyridones, CPO being the prototype, are the sole class of topical antifungal agents that have a completely different mechanism of action than other topical antifungals (azoles and allylamines). It acts through the chelation of polyvalent metal cations, such as ferric (Fe3+) and aluminum (Al3+), thereby causing inhibition of metal-dependent enzymes (cytochromes, catalase, and peroxidase) leading to disruption of cellular activities such as mitochondrial electron transport processes, energy production, and nutrient intake across cell membrane. It has also been known to alter membrane permeability causing blockage of intracellular transport of precursors. Many other mechanisms have also been postulated [Table 1].,,
In in vivo human studies conducted in healthy volunteers, after 2-h contact time of 1% CPO cream applied to the forearm, a high concentration of the drug was detected in the most superficial layer with low levels in deeper layers. CPO penetrates into the hair, and through the epidermis and hair follicles in the sebaceous glands, and dermis with a small portion remaining within the stratum corneum (reservoir effect). The systemic absorption of CPO after intravaginal application was found to be very low with an estimated absorption range of 7–9%.
CPO expresses one of the broadest spectra of antimycotic activity and inhibits nearly all clinically relevant dermatophytes, yeasts, and moulds, including certain frequently azole-resistant Candida species, such as Candida glabrata and Candida krusei. CPO can be both fungistatic and fungicidal depending on the concentration and the duration of contact with target organisms. CPO also shows fungicidal activity against non-growing cells, which makes it a desirable antimycotic in onychomycosis where the slow growth of cells prolongs the duration of required therapy to many months., According to the results of Gupta and Kohli, for dermatophytes, CPO was considerably more effective against all species tested (110 strains of dermatophytes) than itraconazole and ketonazole, being only minimally inferior to terbinafine. For yeasts (14 strains of Candida) and nondermatophyte moulds (9 strains), CPO was the most potent with lowest minimum inhibitory concentration (MIC) values for these fungi, compared with ketoconazole, itraconazole, and terbinafine. Another in vitro study comparing the activity of antifungal agents against dermatophytes revealed that ciclopirox had the second lowest MIC value after clotrimazole among the topical antifungals. CPO has also demonstrated low MIC values and high clinical efficacy against Malassezia globosa and Malassezia restricta, the predominant species involved in pityriasis versicolor and seborrheic dermatitis.
It also displays inhibitory effect over Saccharomyces cerevisiae, and some Aspergillus and Penicillium species, although selected strains of aspergilli have higher MIC values compared with dermatophytes.
CPO has in vitro activity against many gram-positive (Staphylococcus spp., Streptococci, Micrococci, among others) and gram-negative (Proteus spp. and Pseudomonas aeruginosa) bacteria.,, This combined antifungal and antibacterial activity is of particular advantage in the treatment of macerated tinea pedis and “dermatophytosis complex,” both conditions being symptomatic intertriginous fungal affections secondarily infected by bacteria. CPO also exerts activity against Gardnerella vaginalis and Trichomonas vaginalis while sparing Lactobacilli sp., making it a useful topical agent for multiple vaginal infections. It has also been shown to block HIV-1 infection at clinically relevant concentrations [Table 2].
|Table 2: Nonfungal microorganisms (bacteria, viruses, parasitic agents etc.) against which ciclopirox displays inhibitory activity|
Click here to view
CPO also possesses good anti-inflammatory activity that involves inhibition of prostaglandin and leukotriene synthesis in human polymorphonuclear cells. This is mediated by inhibition of 5-lipoxygenase and cyclooxygenase enzymes. It has been reported to be as potent as indomethacin and desoximetasone, and many in vivo studies have reported its anti-inflammatory activity to be superior to most of the other topical antifungals (naftifine, terbinafine, econazole, ketoconazole, miconazole, fluconazole, and oxiconazole).,,
In a double-blind protocol, CPO demonstrated the highest anti-inflammatory property (more than allylamines like terbinafine, azoles, and even 2.5% hydrocortisone). Anti-inflammatory activity of CPO 1% cream has been reported to be similar to that of a combination of CPO 1% and hydrocortisone 1% cream. The implication of the robust anti-inflammatory effect of CPO is its great potential to be used as a single-agent nonsteroidal preparation even for inflamed tinea. The prevalent counterfactual approach of many physicians in India of prescribing antifungal-steroid combination instead of plain antifungal to patients with tinea to provide rapid relief in pruritus is considered to have substantially contributed to the genesis of the emergent epidemic of antifungal therapeutic failures. Sharing the concept and facts that back the strong anti-inflammatory effect of CPO with such physicians may prove instrumental in checking this inappropriate prescribing behavior with a reduction in the incidence of cases of dermatophytosis worsened because of steroids.
| Currently Available Formulations of Ciclopirox (In India)|| |
- Shampoo (for seborrheic dermatitis) – Available in concentrations of 1% and 1.5%
- CPO (for dermatophytic and yeast infections) – 1% cream
- Nail lacquer (for onychomycosis) – 8% to be used daily over the affected nail(s).
The cream formulation, unfortunately, is not stable at room temperature and requires special incipients to make the drug stable and effective for topical use.
The standard recommended dose and duration of application of CPO 1% cream are listed in [Table 3].
|Table 3: Standard recommended dosing and duration of application of ciclopirox olamine 1% cream in different indications|
Click here to view
| Indications and Efficacy of CPO 1% in the Treatment of Different Superficial Mycoses|| |
Dermatophytic (tinea) infections
The results of two multicentric studies that compared CPO cream 1% (ciclopirox 0.77%) with the cream vehicle and clotrimazole cream 1%, respectively, in patients with tinea corporis/cruris showed that the mycological and overall response rates were better in the CPO treated group compared with the vehicle alone while they were almost equal to the clotrimazole-treated group.
CPO demonstrated results superior to clotrimazole in tinea pedis. A prospective, randomized, double-blind, placebo-controlled 8-week clinical study of 100 patients in which ciclopirox gel applied once or twice daily significantly reduced the signs and symptoms, compared with the vehicle with much higher rates of mycologic cure, complete cure, and bacterial count reduction with CPO than the vehicle. The 2007 Cochrane review of topical antifungals for tinea pedis identified good evidence that CPO is efficacious relative to placebo in the management of fungal infections of the skin.
Inflammatory signs and symptoms of tinea pedis have also been shown to respond preferentially to CPO cream 1% as compared with clotrimazole cream 1% in a multicenter, double-blind study of 4 weeks of treatment. The differences between treatment groups were especially marked early in the trial. Clinical response rate (improvement and cure) was significantly higher in the CPO group than in the clotrimazole group at week 1 (93% vs 71%, P value <0.001). At week 2, 26% of 43 patients in the CPO group had a clinical cure, whereas only 2% of those in the clotrimazole group experienced a clinical cure.
Pityriasis versicolor (PV)
CPO cream 1% applied twice daily for 14 days is a well-known efficacious and safe therapy for PV.
Seborrheic dermatitis (SD)
In a recent systematic review on topical treatments for facial SD published by Gupta and Versteeg, topical CPO was accorded a strong recommendation (Grade A practice recommendation) based upon its consistent efficacy established in multiple high-quality randomized controlled trials (RCTs). Various other comparative trials have established relatively superior efficacy, longer duration of persistence of improvement, and/or lesser adverse effects with the use of ciclopirox-based cream/shampoo compared with formulations containing ketoconazole.,,,
Recently, CPO cream demonstrated superior results over placebo in reducing the severity scoring in the treatment of patients affected with atopic dermatitis of the head and neck who tested positive with immunoglobulin E antibodies to Malassezia sympodialis and/or Malassezia furfur.
Candidal infection – vulvovaginal candidiasis (VVC)
The overall incidence of Non candida albicans species (NCAS) causing VVC is on the rise; additionally, the resistance of Candida albicans as well as NCAS to azoles, polyenes, and now even echinocandins (invasive candidiasis) is becoming colossal. Formation of biofilms is a huge contributory factor towards drug resistance. CPO has traditionally been one of the most popular antimycotics for the treatment of vulvovaginal candidiasis. In addition to offering anti-fungal activity against all the major candidal species, CPO is claimed to be effective against azole-resistant Candida species also like C. glabrata, C. krusei, and C. guilliermondii. In addition to anticandidal efficacy, the additional inhibitory effect of CPO on Gardnerella vaginalis and Trichomonas vaginalis (vide supra) makes it an obvious choice over azoles in mixed infections of the female lower genitalia. The effects of CPO cream and pessaries have been found to be similar to miconazole and terconazole creams, and clotrimazole vaginal tablets, respectively.
Candidal infection – extravaginal
The RCT by Bagatell reported that 1% CPO cream demonstrated clear superiority of CPO over placebo and faster onset of improvement and better combined cure rates than clotrimazole.
Ciclopirox topical suspension 0.77% applied twice daily for 7 days to the affected diaper area in babies (6–29 months old) provided statistically significant improvement in severity scores as well as mycological cure.
A phase III study on the use of CPO cream in paediatric population reported excellent safety profile in 95% of the children, and 92% cases showed clinical improvement within a week of application. The authors concluded 1%
CPO cream to be a safe and feasible treatment for superficial cutaneous mycotic infections, especially Candida spp. infection, in children aged between 3 months and 10 years.
| Adverse Effects and Use in Special Situations|| |
Local adverse events are infrequent and include a burning sensation, irritation, redness, pain, or pruritus, and have rarely led to discontinuation of therapy. Allergic contact dermatitis to CPO is rare excepting an anecdotal report. A recent review opines that CPO compares very well with oral antimycotic agents in terms of the benefit/risk ratio because of its excellent tolerability and complete absence of serious adverse effects. It is a pregnancy category B drug and safe to use in patients >10 years of age.,
CPO could be the answer to the emerging antifungal resistance. Even after more than two decades of frequent use of CPO for tinea, PV, and VVC, not even a single case of clinical or in vivo resistance has been reported. Potential of dermatophytes for developing resistance to CPO by biochemical or molecular means is extremely low. The most plausible reasons behind the inability of superficial fungi (both dermatophytes and yeasts) of mounting or evolving mechanisms to resist CPO are its fungicidal mode of action, unique anti-fungal mechanism of action, and a steep dose–response curve.
In conclusion, the unique mechanism of action, in vitro and in vivo efficacy, broad-spectrum antimycotic coverage, additional anti-bacterial and anti-inflammatory activity, well-established safety and excellent tolerance, lack of drug resistance at present coupled with an extremely low likelihood of the development of resistance in future, and easy affordability make CPO 1% cream potentially an ideal topical antifungal for superficial cutaneous mycoses. However, there is a strong need to generate more and fresh evidence to assess its value in the current therapeutic armamentarium of dermatophytosis and other superficial cutaneous mycoses. Its versatility remains unexploited, especially in the wake of the pharmaceutical-driven focus on the development and sale of “newer azoles.” Most importantly, CPO can be instrumental in reducing the menace of steroid-abuse and management of treatment-refractory dermatophytic infections, tinea incognito, mixed infections, and recurrent VVC.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Markus A. Hydroxy-pyridones. Outstanding biological properties. In: Shuster S, editor. Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis. Berlin: Springer-Verlag; 1999. p. 1-10.
Gupta AK. Ciclopirox: An overview. Int J Dermatol 2001;40:305-10.
Subissi A, Monti D, Togni G, Mailland F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 2010;70:2133-52.
Gupta AK, Kohli Y. In vitro
susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro
evaluation of combination antifungal activity. Br J Dermatol 2003;149:296-305.
Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985;29:330-41.
Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM, Lagarde I, Vandermander J, Michel G. Ciclopiroxolamine cream 1%: In vitro
and in vivo
penetration into the stratum comeum. Skin Pharmacol 1991;4:95-9.
Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000;43:S57-69.
Adimi P, Hashemi SJ, Mahmoudi M, Mirhendi H, Shidfar MR, Emmami M, et al
activity of 10 antifungal agents against 320 dermatophyte strains using microdilution method in Tehran. Iran J Pharm Res 2013;12:537-45.
Abrams BB, Hänel H, Hoehler T. Ciclopirox olamine: A hydroxypyridone antifungal agent. Clin Dermatol 1992;9:471-7.
Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997;36:788-92.
Lassus A, Nolting KS, Savopoulos C. Comparison of ciclopirox olamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superrficial mycoses. Clin Ther 1988;10:594-9.
Sonthalia S, Agrawal M. Topical ciclopirox - Recalling a forgotten ally in the fight against cutaneous mycoses. EC Microbiol 2018;14:515-34.
Bogaert H, Cordero C, Ollague W, Savin RC, Shalita AR, Zaias N. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 1986;14:210-6.
Gupta AK, Skinner AR, Cooper EA. Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. Int J Dermatol 2005;44:590-3.
Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007:CD001434.
Kligman AM, Bogaert H, Cordero C. Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: Multicenter, double-blind comparative studies. Clin Ther 1985;7:409-17.
Corte M, Jung K, Linker U, Martini H, Sapp-Boncelet I, Schulz H. Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses 1989;32:200-3.
Gupta AK, Versteeg SG. Topical treatment of facial seborrheic dermatitis: A systematic review. Am J Clin Dermatol 2017;18:193-213.
Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat 2007;18:88-96.
Lorette G, Ermosilla V. Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment. Eur J Dermatol 2006;16:558-64.
Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatol Treat 2002;13:51-60.
Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology 2003;206:233-40.
Mayser P, Kupfer J, Nemetz D, Schäfer U, Nilles M, Hort W, et al
. Treatment of head and neck dermatitis with ciclopiroxolamine cream--results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006;19:153-8.
Bagatell FK. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. Clin Ther 1985;8:41-8.
Gallup E, Plott T, Ciclopirox TS Investigators. A multi- center, open-label study to assess the safety and efficacy of ciclopirox topical suspension 0.77% in the treatment of diaper dermatitis due to Candida albicans. J Drugs Dermatol 2005;4:29-34.
Foti C, Diaferio A, Bonamonte D. Allergic contact dermatitis from ciclopirox olamine. Australas J Dermatol 2001;42:145.
Gómez-Moyano E, Hiraldo Gamero A, Vera Casaño Á, Crespo Erchiga V, González Enseñat MA, Vicente Villa MA, et al
. Phase III study of the efficacy and safety of ciclopirox olamine cream in small children with dermatomycosis. Rev Iberoam Micol 2015;32:164-9.
Patel VM, Schwartz RA, Lambert WC. Topical antiviral and antifungal medications in pregnancy: A review of safety profiles. J Eur Acad Dermatol Venereol 2017;31:1440-6.
[Table 1], [Table 2], [Table 3]